Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma

NCT04925193 is registered in ClinicalTrials.gov with University of Colorado, Denver as lead sponsor.

NCT NCT04925193
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04925193 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Personalized Selinexor-based Therapy for Relapsed/Refractory Multiple Myeloma
Lead sponsor
University of Colorado, Denver
Phase
Phase 2
Overall status
Active, not recruiting
Start date
November 18, 2021
Completion date
November 30, 2026
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

multiple myeloma in relapse